BACKGROUND: Few studies have examined real-world effectiveness of integrated buprenorphine maintenance treatment (BMT) programs in federally qualified health centers (FQHCs). METHODS: Opioid dependent patients (N=266) inducted on buprenorphine between July 2007 and December 2008 were retrospectively assessed at Connecticut's largest FQHC network. Six-month BMT retention and opioid-free time were collected longitudinally from electronic health records; 136 (51.1%) of patients were followed for at least 12 months. RESULTS: Participants had a mean age of 40.1 years, were primarily male (69.2%) and treated by family practitioners (70.3%). Co-morbidity included HCV infection (59.8%), mood disorders (71.8%) and concomitant cocaine use (59%). Retention on BMT was 56.8% at 6 months and 61.6% at 12 months for the subset observed over 1 year. Not being retained on BMT at 12 months was associated with cocaine use (AOR=2.18; 95% CI=1.35-3.50) while prescription of psychiatric medication (AOR=0.36; 95% CI 0.20-0.62) and receiving on-site substance abuse counseling (AOR=0.34; 95% CI 0.19, 0.59) improved retention. Two thirds of the participants experienced at least one BMT gap of 2 or more weeks with a mean gap length of 116.4 days. CONCLUSIONS: Integrating BMT in this large FQHC network resulted in retention rates similarly reported in clinical trials and emphasizes the need for providing substance abuse counseling and screening for and treating psychiatric comorbidity.
BACKGROUND: Few studies have examined real-world effectiveness of integrated buprenorphine maintenance treatment (BMT) programs in federally qualified health centers (FQHCs). METHODS: Opioid dependent patients (N=266) inducted on buprenorphine between July 2007 and December 2008 were retrospectively assessed at Connecticut's largest FQHC network. Six-month BMT retention and opioid-free time were collected longitudinally from electronic health records; 136 (51.1%) of patients were followed for at least 12 months. RESULTS:Participants had a mean age of 40.1 years, were primarily male (69.2%) and treated by family practitioners (70.3%). Co-morbidity included HCV infection (59.8%), mood disorders (71.8%) and concomitant cocaine use (59%). Retention on BMT was 56.8% at 6 months and 61.6% at 12 months for the subset observed over 1 year. Not being retained on BMT at 12 months was associated with cocaine use (AOR=2.18; 95% CI=1.35-3.50) while prescription of psychiatric medication (AOR=0.36; 95% CI 0.20-0.62) and receiving on-site substance abuse counseling (AOR=0.34; 95% CI 0.19, 0.59) improved retention. Two thirds of the participants experienced at least one BMT gap of 2 or more weeks with a mean gap length of 116.4 days. CONCLUSIONS: Integrating BMT in this large FQHC network resulted in retention rates similarly reported in clinical trials and emphasizes the need for providing substance abuse counseling and screening for and treating psychiatric comorbidity.
Authors: Frederick L Altice; R Douglas Bruce; Gregory M Lucas; Paula J Lum; P Todd Korthuis; Timothy P Flanigan; Chinazo O Cunningham; Lynn E Sullivan; Pamela Vergara-Rodriguez; David A Fiellin; Adan Cajina; Michael Botsko; Vijay Nandi; Marc N Gourevitch; Ruth Finkelstein Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Linda Weiss; Julie Netherland; James E Egan; Timothy P Flanigan; David A Fiellin; Ruth Finkelstein; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Lynn E Sullivan; Michael Botsko; Chinazo O Cunningham; Patrick G O'Connor; David Hersh; Jennifer Mitty; Paula J Lum; Richard S Schottenfeld; David A Fiellin Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: P Todd Korthuis; David A Fiellin; Rongwei Fu; Paula J Lum; Frederick L Altice; Nancy Sohler; Mary J Tozzi; Steven M Asch; Michael Botsko; Margaret Fishl; Timothy P Flanigan; Joshua Boverman; Dennis McCarty Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Daniel P Alford; Colleen T LaBelle; Natalie Kretsch; Alexis Bergeron; Michael Winter; Michael Botticelli; Jeffrey H Samet Journal: Arch Intern Med Date: 2011-03-14
Authors: Adam Viera; Daniel J Bromberg; Shannon Whittaker; Bryan M Refsland; Milena Stanojlović; Kate Nyhan; Frederick L Altice Journal: Epidemiol Rev Date: 2020-01-31 Impact factor: 6.222
Authors: Traci R Rieckmann; Nicholas Gideonse; Amanda Risser; Jennifer E DeVoe; Amanda J Abraham Journal: J Behav Health Serv Res Date: 2017-07 Impact factor: 1.505
Authors: Roman Shrestha; Pramila Karki; Frederick L Altice; Oleksandr Dubov; Liana Fraenkel; Tania Huedo-Medina; Michael Copenhaver Journal: AIDS Behav Date: 2018-04
Authors: Yih-Ing Hser; Elizabeth Evans; David Huang; Robert Weiss; Andrew Saxon; Kathleen M Carroll; George Woody; David Liu; Paul Wakim; Abigail G Matthews; Mary Hatch-Maillette; Eve Jelstrom; Katharina Wiest; Paul McLaughlin; Walter Ling Journal: Addiction Date: 2016-01-13 Impact factor: 6.526